Tags:DevelopmentDrugFastHealthInterest
Summary:
NephroGenex is a drug development company focusing on kidney disease. The company is developing Pyridorin™ (pyridoxamine dihydrochloride) as a treatment to slow the progression of diabetic kidney disease. Pyridorin™ has demonstrated a significant treatment effect in slowing the progression of diabetic nephropathy in two Phase IIa clinical trials, and has been awarded Fast Track status by the FDA.
Investors 1
Funding Rounds 1
Mentions in press and media 2
